Rep. Lisa C. McClain Sells Off Shares of AstraZeneca PLC (NASDAQ:AZN)

Key Points

• Representative Lisa C. McClain recently sold between $1,001 and $15,000 in shares of AstraZeneca (NASDAQ:AZN) on June 17, along with several other stock transactions.
• AstraZeneca reported $1.09 EPS for the last quarter, meeting expectations, and had a 16.1% year-over-year revenue increase to $14.46 billion.
• The firm plans to pay a semi-annual dividend of $0.505 per share on September 8, 2023, with a current dividend yield of 200.0%.

Representative Lisa C. McClain (R-Michigan) recently sold shares of AstraZeneca PLC NASDAQ: AZN. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in AstraZeneca stock on June 17th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

AstraZeneca Trading Down 1.5%

AZN traded down $1.1960 during mid-day trading on Monday, hitting $79.7740. The stock had a trading volume of 2,026,946 shares, compared to its average volume of 5,243,087. The stock's fifty day simple moving average is $72.93 and its 200-day simple moving average is $72.25. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a market capitalization of $247.41 billion, a price-to-earnings ratio of 30.02, a price-to-earnings-growth ratio of 1.49 and a beta of 0.36. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. During the same period last year, the business posted $1.24 earnings per share. The business's revenue for the quarter was up 16.1% compared to the same quarter last year. As a group, research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be issued a $0.505 dividend. The ex-dividend date is Friday, August 8th. This represents a yield of 200.0%. AstraZeneca's dividend payout ratio (DPR) is 37.97%.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $86.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. NewSquare Capital LLC grew its position in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company's stock valued at $25,000 after purchasing an additional 218 shares in the last quarter. Banque Transatlantique SA bought a new position in AstraZeneca in the fourth quarter valued at $26,000. Confluence Investment Management LLC bought a new position in AstraZeneca in the first quarter valued at $27,000. Larson Financial Group LLC grew its position in AstraZeneca by 297.9% in the first quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after purchasing an additional 289 shares in the last quarter. Finally, Richardson Financial Services Inc. grew its position in AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company's stock valued at $28,000 after purchasing an additional 149 shares in the last quarter. Institutional investors own 20.35% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.